Head-to-head

BPC-157 vs CJC-1295

A field-by-field comparison of BPC-157 and CJC-1295 drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — recovery & repair and growth hormone — so this page focuses on what each one actually does rather than which is "better".

BPC-157 vs CJC-1295: editorial summary

BPC-157 and CJC-1295 are fundamentally different compounds despite both appearing in peptide-recovery discussions. BPC-157 is primarily associated with preclinical tissue-repair research, while CJC-1295 is a GHRH analogue designed to increase endogenous growth-hormone secretion.

Key considerations

The most important difference is purpose and mechanism. BPC-157's research centres on tissue repair, angiogenesis, gastrointestinal protection and related biological pathways. CJC-1295 acts on the pituitary GHRH receptor and changes GH and IGF-1 signalling.
Their evidence profiles also differ. BPC-157 is rated Emerging with predominantly preclinical evidence, whereas CJC-1295 is rated Moderate and has human pharmacokinetic research.

BPC-157 characteristics

BPC-157 is a 15-amino-acid fragment associated with recovery and repair research. Its principal evidence limitation is the lack of robust human trials for the commonly discussed applications.

CJC-1295 characteristics

CJC-1295 is a GHRH analogue with Moderate evidence. Its DAC and no-DAC forms differ substantially in half-life and dosing frequency.

BPC-157 vs CJC-1295 at a glance

Attribute	BPC-157	CJC-1295
Category	Recovery & repair	Growth hormone
Evidence grade	Emerging	Moderate
Also known as	Body Protection Compound 157, PL 14736	Modified GRF 1-29, DAC:GRF
Chain	15 amino acids (GEPPPGKPADDAGLV)	30 amino acid GHRH analogue
Mechanism	Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining.	Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week.
Reported benefits	Faster tendon, ligament and muscle healing in rodent models · Protective effect on the gastrointestinal lining, including NSAID-induced damage · Reduced local inflammation around injury sites · Anecdotal relief from tendinopathy and joint pain	Elevated GH and IGF-1 across the dosing window · Improved sleep depth reported by most users · Supports lean mass retention and fat oxidation
Reported side effects	Injection-site irritation · Transient dizziness or nausea · Unknown long-term safety profile	Water retention · Tingling or numbness in hands · Head rush and flushing after injection · Elevated fasting glucose at higher doses
Half-life	Approximately 4 hours (stable oral form debated)	~30 minutes without DAC; ~6–8 days with DAC
Administration	Subcutaneous injection; oral capsules used for gut-specific goals	Subcutaneous injection, typically before bed on an empty stomach
Dosing overview	Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks	100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version
Storage	Lyophilised powder refrigerated; reconstituted vials 2–8 °C, used within ~30 days	Refrigerate reconstituted product; protect from light and avoid shaking
Legal status	Not FDA-approved. Research-chemical status in most countries; prohibited in sport.	Not FDA-approved. Prescribed off-label by some clinics; banned in sport.

Key differences between BPC-157 and CJC-1295

Different categories, different goals

BPC-157 is indexed under recovery & repair, while CJC-1295 sits under growth hormone. They are not substitutes for one another: BPC-157 is described as "A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints." and CJC-1295 as "A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it."

Mechanism of action

BPC-157: Appears to upregulate growth-hormone receptor expression in tendon fibroblasts and promote angiogenesis via the VEGFR2–Akt–eNOS pathway, accelerating the formation of new blood vessels at an injury site. It also modulates nitric oxide signalling and appears protective of the gut lining. CJC-1295: Binds pituitary GHRH receptors to increase both the amplitude of GH pulses and total GH secretion. The DAC (drug affinity complex) version binds serum albumin, extending the half-life from minutes to about a week.

Evidence quality is not equal

BPC-157 carries a Emerging evidence grade and CJC-1295 a Moderate grade on this index. The grade describes the quality of published human data, not how well a compound works — CJC-1295 has the better-documented record of the two, and claims made about BPC-157 rest on thinner human evidence.

Half-life and dosing frequency

BPC-157 is listed at approximately 4 hours (stable oral form debated); CJC-1295 at ~30 minutes without dac; ~6–8 days with dac. That difference is what drives the reported schedules: Commonly cited in literature at 200–500 mcg once or twice daily for 4–8 weeks versus 100 mcg (no-DAC) 1–3× daily, or 1–2 mg weekly for the DAC version

Route of administration

BPC-157 is administered by subcutaneous injection; oral capsules used for gut-specific goals. CJC-1295 is administered by subcutaneous injection, typically before bed on an empty stomach.

Legal and regulatory status differs

BPC-157: Not FDA-approved. Research-chemical status in most countries; prohibited in sport. CJC-1295: Not FDA-approved. Prescribed off-label by some clinics; banned in sport. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.

Handling and storage

BPC-157 is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c, used within ~30 days. CJC-1295 is stored refrigerate reconstituted product; protect from light and avoid shaking.

What BPC-157 and CJC-1295 have in common

On the attributes tracked in this database — category, evidence grade, mechanism, half-life, administration, dosing overview, storage and legal status — BPC-157 and CJC-1295 share no identical values. They are compared here because they come up together in the same searches, not because they overlap.

Each compound in brief

BPC-157

Recovery & repair · Emerging evidence

A synthetic fragment of a protein found in gastric juice, widely used in the recovery community for tendon, gut and soft-tissue complaints.

Considerations: Nearly all evidence is preclinical (rodent); robust human trials are absent · Injected near the injury site is the common anecdotal practice, though systemic effects are proposed · Banned by WADA for competing athletes

CJC-1295

Growth hormone · Moderate evidence

A growth-hormone-releasing hormone analogue that raises the baseline of natural GH output rather than replacing it.

Considerations: Usually paired with a GHRP such as Ipamorelin for a synergistic pulse · No-DAC (Mod GRF 1-29) suits pulsatile dosing; DAC suits steady elevation · GH elevation is not desirable for everyone — screen for cancer history

Frequently asked questions

Are BPC-157 and CJC-1295 similar?

Not mechanistically. BPC-157 is primarily studied in tissue-repair models, while CJC-1295 stimulates the GHRH pathway and increases GH secretion.

Which has more human evidence?

CJC-1295 has human pharmacokinetic research. BPC-157's commonly discussed recovery applications remain predominantly supported by preclinical research.

Are they interchangeable?

No. Their biological targets and research purposes are substantially different.